## 1,4-Butanediol Dimethacrylate (BDDMA) Explained
1,4-Butanediol dimethacrylate (BDDMA) is a **monomer**, meaning it is a small molecule that can react with other monomers to form long chains, called polymers. BDDMA is specifically a **cross-linking monomer**, meaning it has two reactive sites, allowing it to connect different polymer chains together, creating a **network structure**.
**Why is BDDMA important for research?**
BDDMA is crucial in various research fields due to its role in creating **highly stable and durable materials**. Here's a breakdown:
* **Biomedical Applications:**
* **Dental Materials:** BDDMA is used in **dental resins and composites**, making them strong and resistant to wear and tear. It also improves their biocompatibility and adhesion to teeth.
* **Tissue Engineering:** It's used in **hydrogels** for 3D cell culture and tissue regeneration. Its cross-linking properties allow for the creation of porous and biocompatible scaffolds that mimic the natural environment of tissues.
* **Drug Delivery:** BDDMA is incorporated in **microspheres and nanoparticles**, enabling controlled release of medications and targeted drug delivery.
* **Materials Science:**
* **Polymers:** BDDMA contributes to the development of **high-performance polymers** with improved mechanical strength, thermal stability, and resistance to chemicals.
* **Coatings:** It is used in **protective coatings** for various surfaces, providing resistance to scratches, abrasions, and environmental factors.
* **Other Applications:**
* **Adhesives:** BDDMA enhances the adhesion of adhesives, leading to stronger bonds and improved performance.
* **Optoelectronics:** Its unique optical properties are utilized in the development of **optical fibers and other light-guiding materials**.
**Importance in Research:**
BDDMA's versatility and unique properties make it a vital component in research across various disciplines. Its potential for creating innovative and functional materials drives advancements in:
* **Biomedical Engineering:** Developing new materials for implants, drug delivery, and regenerative medicine.
* **Materials Science:** Discovering new polymers with tailored properties for specific applications.
* **Chemistry:** Understanding the mechanisms of cross-linking reactions and polymer network formation.
* **Nanotechnology:** Designing and manufacturing nanomaterials with unique properties.
**Overall, 1,4-butanediol dimethacrylate plays a significant role in expanding the possibilities of creating advanced materials with diverse functionalities, making it a key ingredient in research and technological innovation.**
| ID Source | ID |
|---|---|
| PubMed CID | 16387 |
| CHEMBL ID | 3184875 |
| SCHEMBL ID | 25426 |
| MeSH ID | M0268831 |
| Synonym |
|---|
| 1,4-butylene glycol dimethacrylate |
| tetramethylene dimethacrylate |
| 1,4-butanediol dimethacrylate, 95%, contains 200-300 ppm mehq as inhibitor |
| hsdb 5467 |
| 1,4-butanediol dimethacrylate |
| butylene dimethacrylate |
| 2-propenoic acid, 2-methyl-, 1,4-butanediyl ester |
| tetramethylene methacrylate |
| tetramethylene glycol dimethacrylate |
| x 970 |
| 1,4-butylene dimethacrylate |
| oligotetramethylene glycol dimethacrylate |
| ccris 7046 |
| einecs 218-218-1 |
| methacrylic acid, tetramethylene ester |
| 4-(2-methylprop-2-enoyloxy)butyl 2-methylprop-2-enoate |
| 2082-81-7 |
| FT-0650574 |
| kx6732he0u , |
| 2-propenoic acid, 2-methyl-, 1,1'-(1,4-butanediyl) ester |
| unii-kx6732he0u |
| ec 218-218-1 |
| tox21_301681 |
| dtxsid4044870 , |
| butane-1,4-diyl bis(2-methylprop-2-enoate) |
| cas-2082-81-7 |
| dtxcid2024870 |
| NCGC00256263-01 |
| AM84724 |
| AKOS015902993 |
| 1,4-butanediol dimethacrylate [inci] |
| 1,4-butanediol dimethacrylate [hsdb] |
| SCHEMBL25426 |
| 4-(methacryloyloxy)butyl 2-methylacrylate # |
| CHEMBL3184875 |
| butane-1,4-diyl bis(2-methylacrylate) |
| mfcd00008594 |
| tetramethylene glycol dimethacrylate (stabilized with mehq) |
| J-013661 |
| 1,4-butanediol dimethacrylate(6.4cp(20 degrees c)) |
| 1,4-butanediol dimethacrylate,min. 90% |
| T3488 |
| Q27282479 |
| A852249 |
| D92705 |
| 1,4-butanediol dimethacrylate 100 microg/ml in acetonitrile |
| CAA08281 |
| 4-[(2-methylprop-2-enoyl)oxy]butyl 2-methylprop-2-enoate |
| CS-W010428 |
| Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Luciferase | Photinus pyralis (common eastern firefly) | Potency | 89.3584 | 0.0072 | 15.7588 | 89.3584 | AID1224835 |
| cytochrome P450, family 19, subfamily A, polypeptide 1, isoform CRA_a | Homo sapiens (human) | Potency | 1.5355 | 0.0017 | 23.8393 | 78.1014 | AID743083 |
| thyroid stimulating hormone receptor | Homo sapiens (human) | Potency | 0.6113 | 0.0016 | 28.0151 | 77.1139 | AID1259385 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (5.56) | 18.2507 |
| 2000's | 14 (77.78) | 29.6817 |
| 2010's | 3 (16.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 20 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||